Zacks Research Analysts Reduce Earnings Estimates for ESPR
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at Zacks Research decreased their Q3 2025 earnings per share estimates for Esperion Therapeutics in a report issued on Wednesday, February 12th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of ($0.02) for the quarter, down from […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at Zacks Research decreased their Q3 2025 earnings per share estimates for Esperion Therapeutics in a report issued on Wednesday, February 12th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of ($0.02) for the quarter, down from […]
